MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Pancreas, Pancreatic
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
Organization & Developments: Infinity
Parents
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
Children
2006: $70m Medimmune licensing agreement (2006)
2008: Infinity Snags $75 Million Through Alliance with Purdue Pharma and Mundipharma (2008)
2011: Infinity Pharmaceuticals Snags $50M Extension From Mundipharma (2011)
2012: Infinity Drug Fails in Pancreatic Cancer Trial, Shares Fall (2012)
2016: Biotech Forum Daily Digest: Heading Down; Valeant's Plan; What I Am Buying Now - Dynavax Technologies Corporation (NASDAQ:DVAX)
2016: Infinity Pharmaceuticals (NASDAQ:INFI) lost two-thirds of its value as it announced poor results from a mid-stage study assessing lead product candidate duvelisib for the treatment of refractory indolent non-Hodgkin lymphoma.
2020: Infinity Pharmaceuticals: Cash Position Boosted, Multiple Readouts Over The Next Year_seekingalpha.com
2021: Biotech Analysis Central Preview Series: Infinity Pharmaceuticals
2022: Infinity Pharmaceuticals: Waiting For A Deal_seekingalpha.com
2023: Infinity comes to an end with Chapter 11 bankruptcy filing
Cancer: Drugs
Jumps
*Key People: Infinity
Finance & Acquisitions: Infinity